AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18343646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg
Number of subjects: 20
Study 18343646 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (SFC) 50/250 microg
Number of subjects: 20
Study 15961340 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Proportional Integral Derivative Controller (GPIDC)
Number of subjects: 12
Study 15961340 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Fuzzy Logic Controller (GFLC)
Number of subjects: 12
Study 15961340 — intervention group
Group type: COMPARATOR
Intervention: Manual Control
Number of subjects: 12
Study 14633181 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily for 8 weeks
Number of subjects: 454
Study 14633181 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for 8 weeks
Number of subjects: 454
Study 14633181 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms received ribavirin (1000-1200 mg orally per day) starting at week 4
Number of subjects: 454
Study 10710017 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted decrease in sedentary behaviors
Number of subjects: 90
Study 10710017 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted increase in physical activity
Number of subjects: 90
Study 9154538 — intervention group
Group type: COMPARATOR
Intervention: Original formulation of amoxicillin/clavulanate potassium (Augmentin) administered tid for 10 days (40/10 mg/kg/day)
Number of subjects: 868
Study 9154538 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of amoxicillin/clavulanate potassium (Augmentin) administered bid for 10 days (45/6.4 mg/kg/day)
Number of subjects: 868
Study 9154538 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of amoxicillin/clavulanate potassium (Augmentin) administered bid for 5 days (45/6.4 mg/kg/day)
Number of subjects: 868
Study 8587702 — intervention group
Group type: COMPARATOR
Intervention: 0.65 g/kg alcohol
Number of subjects: 0
Study 2670309 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain tablets of pyronaridine (0.5 g on day 1, 0.3 g on day 2)
Number of subjects: 64
Study 2670309 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated tablets of pyronaridine (0.4 g x 2 on day 1, 0.4 g on day 2)
Number of subjects: 64
Study 779663 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg capsules
Number of subjects: 35
Study 779663 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 35
Study 779663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31896134 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure
Number of subjects: 60
Study 31896134 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement error term included in models
Number of subjects: 60
Study 31896134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models
Number of subjects: 60
Study 31277832 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6Dv2SF‐36 (full questionnaire with 36 items)
Number of subjects: 782
Study 31277832 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6Dv2ind‐10 (subset questionnaire with 10 items)
Number of subjects: 782
Study 31277832 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6Dv2ind‐6 (independent instrument with 6 items)
Number of subjects: 782
Study 28324167 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg subcutaneous injection every 4 weeks
Number of subjects: 144
Study 28324167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 28324167 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 144
Study 25387762 — intervention group
Group type: EXPERIMENTAL
Intervention: High trust in decision-making authorities
Number of subjects: 3
Study 25387762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trust in decision-making authorities
Number of subjects: 3
Study 25387762 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of outcome and procedural fairness
Number of subjects: 3
Study 24375468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0
Study 24375468 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training
Number of subjects: 0
Study 24375468 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 0
Study 22149065 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU) and Calcium (2 g)
Number of subjects: 85
Study 22149065 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (800 IU)
Number of subjects: 85
Study 18495735 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 6 weeks through week 96
Number of subjects: 279
Study 18495735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 18495735 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 7.5 mg/kg (after dose escalation starting at week 36)
Number of subjects: 279
Study 18495735 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 279
Study 17459557 — intervention group
Group type: COMPARATOR
Intervention: Unmodified acidic soft drink
Number of subjects: 15
Study 17459557 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental acidic soft drink with 0.02% polyphosphate
Number of subjects: 15
Study 17459557 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental acidic soft drink with 0.02% polyphosphate and 0.01% calcium
Number of subjects: 15
Study 17459557 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental acidic soft drink with 0.02% polyphosphate and 0.03% xanthan gum
Number of subjects: 15
Study 17459557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water
Number of subjects: 15
Study 16343085 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 170
Study 16343085 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed formula (EHF)
Number of subjects: 170
Study 12475462 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 41
Study 12475462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9666876 — intervention group
Group type: COMPARATOR
Intervention: CBZ alone (n = 23)
Number of subjects: 66
Study 9666876 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ + T3 (n = 19)
Number of subjects: 66
Study 9666876 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ + Triac (n = 24)
Number of subjects: 66
Study 8944402 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam (0.5 and 1 mg)
Number of subjects: 12
Study 8944402 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 12
Study 8944402 — intervention group
Group type: COMPARATOR
Intervention: alprazolam (1 mg)
Number of subjects: 12
Study 8944402 — intervention group
Group type: COMPARATOR
Intervention: alprazolam (1 mg) and lorazepam (2 mg)
Number of subjects: 12
Study 1956688 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphate quinine (30 mg/kg bw/day in three divided doses)
Number of subjects: 65
Study 1956688 — intervention group
Group type: COMPARATOR
Intervention: fansidar (sulphadoxine 20-30 mg/kg bw/day, single dose)
Number of subjects: 65
Study 6111670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (5 days of antibiotic prophylaxis, starting just before surgery)
Number of subjects: 2137
Study 6111670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2137
Study 30900195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted virtual mind–body group intervention
Number of subjects: 0
Study 30900195 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (control)
Number of subjects: 0
Study 30676542 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) 25 μg/h applied 14 hours before operation
Number of subjects: 60
Study 30676542 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 60
Study 30676542 — intervention group
Group type: COMPARATOR
Intervention: Intravenous continuous fentanyl (25 μg/h) with loading dose (25 μg) in control group
Number of subjects: 60
Study 27923167 — intervention group
Group type: EXPERIMENTAL
Intervention: Running 2.0 V‐Lock™ (Arm 1)
Number of subjects: 90
Study 27923167 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 Vicryl™ figure‐of‐eight (Arm 2)
Number of subjects: 90
Study 27923167 — intervention group
Group type: EXPERIMENTAL
Intervention: Running 0 Vicryl™ with Lapra‐Ty® (Arm 3)
Number of subjects: 90
Study 25958101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic group (streptokinase 250,000 IU in 50 ml saline)
Number of subjects: 40
Study 25958101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic group (streptokinase)
Number of subjects: 40
Study 25958101 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 ml saline)
Number of subjects: 40
Study 23648056 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ropivacaine (3mg/kg)
Number of subjects: 60
Study 23648056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ropivacaine (1.5mg/kg)
Number of subjects: 60
Study 23648056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21741748 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic salpingectomy (SPLS)
Number of subjects: 60
Study 21741748 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic salpingectomy
Number of subjects: 60
Study 19070841 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb immobilisation (lightweight below-elbow cast with thumb free)
Number of subjects: 8
Study 19070841 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-arm immobilisation
Number of subjects: 8
Study 19070841 — intervention group
Group type: COMPARATOR
Intervention: No immobilisation (unrestricted driving)
Number of subjects: 8
Study 16988629 — intervention group
Group type: EXPERIMENTAL
Intervention: Insert protocol (atropine 1%, diclofenac 0.1% collyrium and Mydriasert)
Number of subjects: 51
Study 16988629 — intervention group
Group type: COMPARATOR
Intervention: Drop protocol (atropine 1%, diclofenac 0.1%, tropicamide 0.5%, and phenylephrine 10% collyrium)
Number of subjects: 51
Study 16988629 — intervention group
Group type: EXPERIMENTAL
Intervention: Insert protocol
Number of subjects: 51
Study 16988629 — intervention group
Group type: COMPARATOR
Intervention: Drop protocol
Number of subjects: 51
Study 15316580 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I alone
Number of subjects: 187
Study 15316580 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI stopped 7 days before (131)I
Number of subjects: 187
Study 15316580 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI until (131)I application
Number of subjects: 187
Study 15316580 — intervention group
Group type: COMPARATOR
Intervention: Control group (MMI pretreated)
Number of subjects: 187
Study 10945550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystocholangiography (CCC)
Number of subjects: 76
Study 10945550 — intervention group
Group type: COMPARATOR
Intervention: Cystic duct cholangiography (CDC)
Number of subjects: 76
Study 1736038 — intervention group
Group type: COMPARATOR
Intervention: Patients with liver disease
Number of subjects: 60
Study 1736038 — intervention group
Group type: COMPARATOR
Intervention: Patients with severe malnutrition
Number of subjects: 60
Study 1736038 — intervention group
Group type: COMPARATOR
Intervention: Patients with liver disease, septicemia, renal insufficiency, and those on long-term glucose feeding
Number of subjects: 60
Study 1736038 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality rate in study patients
Number of subjects: 60
Study 30720733 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 45
Study 30720733 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinative training
Number of subjects: 45
Study 30720733 — intervention group
Group type: COMPARATOR
Intervention: Assisted homework sessions
Number of subjects: 45
Study 30537982 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neurocognitive training for at least 10 days, continued for 4 weeks postoperatively
Number of subjects: 45
Study 30537982 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 45
Study 26195621 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsion adapter
Number of subjects: 10
Study 26195621 — intervention group
Group type: COMPARATOR
Intervention: Rigid placebo
Number of subjects: 10
Study 25435806 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST-guided ProSeal LMA insertion
Number of subjects: 140
Study 25435806 — intervention group
Group type: COMPARATOR
Intervention: IT-assisted ProSeal LMA insertion
Number of subjects: 140
Study 22519806 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 80
Study 22519806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19995857 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based individualized training (IT)
Number of subjects: 110
Study 19995857 — intervention group
Group type: COMPARATOR
Intervention: General training (GT)
Number of subjects: 110
Study 19018087 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Oxaliplatin (CAP/OX)
Number of subjects: 3494
Study 19018087 — intervention group
Group type: COMPARATOR
Intervention: Infusional Fluorouracil plus Oxaliplatin (FU/OX)
Number of subjects: 3494
Study 16283925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light treatment (8,500 Lux) for one hour a day
Number of subjects: 81
Study 16283925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim red light treatment (<10 Lux) for one hour a day
Number of subjects: 81
Study 16283925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dim red light treatment)
Number of subjects: 81
Study 12817911 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEpo) treatment
Number of subjects: 8
Study 12817911 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated subjects)
Number of subjects: 8
Study 10229041 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 8904622 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine 100 mg once daily
Number of subjects: 531
Study 8904622 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine 200 mg once daily
Number of subjects: 531
Study 8904622 — intervention group
Group type: EXPERIMENTAL
Intervention: Minaprine 300 mg once daily
Number of subjects: 531
Study 8904622 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 150 mg once daily (75 mg during the first week)
Number of subjects: 531
Study 2011462 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized marker type procedure
Number of subjects: 0
Study 2011462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramodal conditions with physical characteristics of markers
Number of subjects: 0
Study 6365016 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally staffed community
Number of subjects: 347
Study 6365016 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer confrontation community
Number of subjects: 347
Study 6365016 — intervention group
Group type: COMPARATOR
Intervention: Eclectic program (professionals and paraprofessionals)
Number of subjects: 347
Study 6365016 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal-only group
Number of subjects: 347
Study 6365016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both successful communities
Number of subjects: 347
Study 31340956 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated GP care plus treatment as usual (includes GP training in cognitive behavioural skills, GP supervision, and written/audio-visual materials for GPs and participants)
Number of subjects: 240
Study 31340956 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 240
Study 29959802 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-1077/CD
Number of subjects: 16
Study 27223813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine plus cisplatin
Number of subjects: 151
Study 27223813 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin
Number of subjects: 151
Study 24317208 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback electromyography (n = 16)
Number of subjects: 29
Study 24317208 — intervention group
Group type: COMPARATOR
Intervention: Common physiotherapy (n = 13)
Number of subjects: 29
Study 23649826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 1426
Study 20947383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 26
Study 20947383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18536386 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianglingwan administered from the fifth day of the menstrual cycle for 3 weeks every month for three months
Number of subjects: 54
Study 16284750 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine administration
Number of subjects: 10
Study 16284750 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 10
Study 15023658 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA plus CLA (3.2g CLA)
Number of subjects: 19
Study 15023658 — intervention group
Group type: COMPARATOR
Intervention: ALA plus placebo (soybean oil)
Number of subjects: 19
Study 10875786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis vaccine (exact details not specified)
Number of subjects: 4400
Study 10875786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 4400
Study 8927950 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b
Number of subjects: 30
Study 1740374 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pilocarpine
Number of subjects: 36
Study 1740374 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% pilocarpine
Number of subjects: 36
Study 1740374 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide (0.4%)
Number of subjects: 36
Study 6653131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of orphenadrine (35 mg) and paracetamol (450 mg) tablets, 1 tablet 3 times daily
Number of subjects: 44
Study 6653131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30866917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial digital and organisational intervention combining risk stratification algorithms, practice-based quality improvement, and health monitoring and coaching.
Number of subjects: 235800
Study 30866917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial digital and organisational intervention
Number of subjects: 235800
Study 30340939 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen (oestradiol hemihydrate patches)
Number of subjects: 140
Study 30340939 — intervention group
Group type: COMPARATOR
Intervention: Oral oestrogen (oestradiol valerate pills)
Number of subjects: 140
Study 26903143 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based robot-guided therapy
Number of subjects: 41
Study 26903143 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based robot-guided therapy
Number of subjects: 41
Study 24825868 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 796
Study 24825868 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with H1N1pdm09 in 2009-2010
Number of subjects: 796
Study 24825868 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection with H3N2 in 2010
Number of subjects: 796
Study 21937520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 107
Study 21937520 — intervention group
Group type: COMPARATOR
Intervention: Usual care rehabilitation
Number of subjects: 107
Study 21937520 — intervention group
Group type: COMPARATOR
Intervention: Both AIT and Usual care
Number of subjects: 107
Study 20040875 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF agents
Number of subjects: 0
Study 17324131 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 728
Study 17324131 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 728
Study 17324131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study 17324131 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 728
Study 16351370 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased attachment security through implicit and explicit priming techniques
Number of subjects: 0
Study 16351370 — intervention group
Group type: COMPARATOR
Intervention: Dispositional attachment-related anxiety and avoidance
Number of subjects: 0
Study 12028174 — intervention group
Group type: EXPERIMENTAL
Intervention: Care protocol followed by community nurses for 6 months after discharge
Number of subjects: 89
Study 12028174 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 89
Study 9448170 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., colloidal bismuth subcitrate 120 mg q.i.d. for 7 days
Number of subjects: 182
Study 9448170 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 7 days
Number of subjects: 182
Study 7879787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (not specified)
Number of subjects: 5306
Study 2243689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both canaliculi occluded
Number of subjects: 20
Study 2243689 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocanalicular obstruction (either upper or lower)
Number of subjects: 20
Study 487808 — intervention group
Group type: EXPERIMENTAL
Intervention: Active T‐shaped IUD releasing 65 micrograms/day of progesterone
Number of subjects: 1320
Study 487808 — intervention group
Group type: COMPARATOR
Intervention: Plain T‐shaped IUD
Number of subjects: 1320
Study 31419353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (ATG, n = 13)
Number of subjects: 26